{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T01:09:17Z","timestamp":1784423357038,"version":"3.55.0"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008333","name":"University of Alabama at Birmingham","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008333","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p>RHOBTB2 is a member of the Rho GTPases subfamily of signaling proteins, known tumor suppressors whose loss of function and decreased expression is associated with cancer onset. Beyond its cancer-related role, RHOBTB2 is implicated in rare neurodevelopmental disorders, specifically <jats:italic>RHOBTB2<\/jats:italic>-related disorders, recognized in 2018 as a subtype of developmental and epileptic encephalopathies (DEE). Common symptoms of these disorders include early-onset epilepsy, severe intellectual disability, microcephaly, and movement disorders. Few studies have investigated patient variants associated with <jats:italic>RHOBTB2<\/jats:italic>-related disorders, and the impact of these variants on protein function remains unclear. Limited research suggests that the accumulation of RHOBTB2 in neural tissues contributes to the development of DEE. Similarly, preclinical studies indicate that missense variants near or in the BTB domain of RHOBTB2 result in decreased degradation of RHOBTB2 and the onset of DEE, whereas variants in the GTPase domain cause more variable neurodevelopmental symptoms, but do not impair proteasomal degradation of RHOBTB2. However, the exact pathophysiological mechanisms are unclear and may differ across variants. Current treatment approaches for individuals with <jats:italic>RHOBTB2<\/jats:italic>-related DEE involve the use of antiseizure medications to decrease seizures; however, no treatments have been identified that address the other symptoms or the underlying pathophysiological mechanisms associated with these disorders. Overall, RHOBTB2 remains an understudied protein with limited information on its function and how it contributes to disease mechanisms. This review provides an overview of the current knowledge of RHOBTB2 function<jats:italic>,<\/jats:italic> with an emphasis on its association with neurodevelopmental disorders through an analysis of preclinical studies and case reports that link individual variants with clinical features.<\/jats:p>","DOI":"10.3389\/fped.2024.1448793","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T06:18:53Z","timestamp":1734329933000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Variants in RHOBTB2 associated with cancer and rare developmental and epileptic encephalopathy"],"prefix":"10.3389","volume":"12","author":[{"given":"Elaina","family":"Solano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Foksinska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camerron M.","family":"Crowder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.ajhg.2022.03.002","article-title":"Germline variants in tumor suppressor FBXW7 lead to impaired ubiquitination and a neurodevelopmental syndrome","volume":"109","author":"Stephenson","year":"22","journal-title":"Am J Hum Genet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41525-023-00377-6","article-title":"Neurodevelopmental disorders and cancer networks share pathways, but differ in mechanisms, signaling strength, and outcome","volume":"8","author":"Yavuz","year":"2023","journal-title":"NPJ Genom Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1038\/s41431-019-0392-7","article-title":"Three de novo DDX3X variants associated with distinctive brain developmental abnormalities and brain tumor in intellectually disabled females","volume":"27","author":"Scala","year":"2019","journal-title":"Eur J Hum Genet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s12551-023-01054-9","article-title":"Neurodevelopmental disorders, like cancer, are connected to impaired chromatin remodelers, PI3K\/mTOR, and PAK1-regulated MAPK","volume":"15","author":"Nussinov","year":"2023","journal-title":"Biophys Rev"},{"key":"B5","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.gene.2011.07.018","article-title":"RhoBTB2 (DBC2) functions as tumor suppressor via inhibiting proliferation, preventing colony formation and inducing apoptosis in breast cancer cells","volume":"486","author":"Mao","year":"2011","journal-title":"Gene"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1093\/nar\/29.5.1068","article-title":"The dictyostelium discoideum family of rho-related proteins","volume":"29","author":"Rivero","year":"2001","journal-title":"Nucleic Acids Res"},{"key":"B7","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.cell.2007.05.018","article-title":"GEFs and GAPs: critical elements in the control of small G proteins","volume":"129","author":"Bos","year":"2007","journal-title":"Cell"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1101\/gad.11.18.2295","article-title":"Rho GTPases and signaling networks","volume":"11","author":"Van Aelst","year":"1997","journal-title":"Genes Dev"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2713","DOI":"10.1242\/jcs.114.15.2713","article-title":"Rho GTPases and cell migration","volume":"114","author":"Ridley","year":"2001","journal-title":"J Cell Sci"},{"key":"B10","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1042\/bj20031041","article-title":"Rho GTPases have diverse effects on the organization of the actin filament system","volume":"377","author":"Aspenstr\u00f6m","year":"2004","journal-title":"Biochem J"},{"key":"B11","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S0378-1119(02)00980-0","article-title":"Genomic organization and expression profile of the small GTPases of the RhoBTB family in human and mouse","volume":"298","author":"Ramos","year":"2002","journal-title":"Gene"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.3390\/cells10123395","article-title":"Pathophysiological mechanisms in neurodevelopmental disorders caused by rac GTPases dysregulation: what's behind neuro-RACopathies","volume":"10","author":"Scala","year":"2021","journal-title":"Cells"},{"key":"B13","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.ajhg.2020.01.018","article-title":"Opposite modulation of RAC1 by mutations in TRIO is associated with distinct, domain-specific neurodevelopmental disorders","volume":"106","author":"Barbosa","year":"2020","journal-title":"Am J Hum Genet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.1093\/brain\/awac106","article-title":"Variant-specific changes in RAC3 function disrupt corticogenesis in neurodevelopmental phenotypes","volume":"145","author":"Scala","year":"2022","journal-title":"Brain"},{"key":"B15","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1136\/jmedgenet-2022-108483","article-title":"Gain-of-function p.F28S variant in RAC3 disrupts neuronal differentiation, migration and axonogenesis during cortical development, leading to neurodevelopmental disorder","volume":"60","author":"Nishikawa","year":"2023","journal-title":"J Med Genet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.ajhg.2017.12.015","article-title":"Functional dysregulation of CDC42 causes diverse developmental phenotypes","volume":"102","author":"Martinelli","year":"2018","journal-title":"Am J Hum Genet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1093\/molbev\/msl145","article-title":"Evolution of the rho family of ras-like GTPases in eukaryotes","volume":"24","author":"Boureux","year":"2007","journal-title":"Mol Biol Evol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0076-6879(07)00408-9","article-title":"Regulation of RhoBTB2 by the Cul3 ubiquitin ligase complex","volume":"439","author":"Wilkins","year":"2008","journal-title":"Meth Enzymol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ajhg.2017.11.008","article-title":"Missense variants in RHOBTB2 cause a developmental and epileptic encephalopathy in humans, and altered levels cause neurological defects in Drosophila","volume":"102","author":"Straub","year":"2018","journal-title":"Am J Hum Genet"},{"key":"B20","doi-asserted-by":"publisher","first-page":"100885","DOI":"10.1016\/j.gim.2023.100885","article-title":"Genotype-phenotype correlations in RHOBTB2-associated neurodevelopmental disorders","volume":"25","author":"Langhammer","year":"2023","journal-title":"Genet Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e1929","DOI":"10.1002\/mgg3.1929","article-title":"Developmental and epileptic encephalopathy related to a heterozygous variant of the RHOBTB2 gene: a case report from French Guiana","volume":"10","author":"Defo","year":"2022","journal-title":"Mol Genet Genomic Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s42494-021-00056-y","article-title":"RHOBTB2 Gene associated epilepsy and paroxysmal movement disorder: two cases report and literature review","volume":"3","author":"Niu","year":"2021","journal-title":"Acta Epileptologica"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e418","DOI":"10.1212\/NXG.0000000000000418","article-title":"Acute encephalopathy after head trauma in a patient with a RHOBTB2 mutation","volume":"6","author":"Knijnenburg","year":"2020","journal-title":"Neurol Genet"},{"key":"B24","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/epi.16427","article-title":"Genetic diagnoses in epilepsy: the impact of dynamic exome analysis in a pediatric cohort","volume":"61","author":"Rochtus","year":"2020","journal-title":"Epilepsia"},{"key":"B25","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.parkreldis.2020.05.031","article-title":"Paroxysmal movement disorder with response to carbamazepine in a patient with RHOBTB2 developmental and epileptic encephalopathy","volume":"76","author":"Spagnoli","year":"2020","journal-title":"Parkinsonism Relat Disord"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1002\/humu.23550","article-title":"de novo variants in RHOBTB2, an atypical rho GTPase gene, cause epileptic encephalopathy","volume":"39","author":"Belal","year":"2018","journal-title":"Hum Mutat"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e1539","DOI":"10.1212\/WNL.0000000000011543","article-title":"RHOBTB2 mutations expand the phenotypic spectrum of alternating hemiplegia of childhood","volume":"96","author":"Zagaglia","year":"2021","journal-title":"Neurology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1111\/j.1745-7254.2008.00773.x","article-title":"Rho GTPases of the RhoBTB subfamily and tumorigenesis","volume":"29","author":"Berthold","year":"2008","journal-title":"Acta Pharmacol Sin"},{"key":"B29","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.1016\/j.yexcr.2008.09.005","article-title":"Characterization of RhoBTB-dependent Cul3 ubiquitin ligase complexes\u2013evidence for an autoregulatory mechanism","volume":"314","author":"Berthold","year":"2008","journal-title":"Exp Cell Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/bs.apcsb.2017.08.003","article-title":"Homo- and heterodimerization of proteins in cell signaling: inhibition and drug design","volume":"111","author":"Singh","year":"2018","journal-title":"Adv Protein Chem Struct Biol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1101\/gad.1177904","article-title":"RhoBTB2 is a substrate of the mammalian Cul3 ubiquitin ligase complex","volume":"18","author":"Wilkins","year":"2004","journal-title":"Genes Dev"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1038\/sj.onc.1207373","article-title":"Regulation of apoptosis proteins in cancer cells by ubiquitin","volume":"23","author":"Zhang","year":"2004","journal-title":"Oncogene"},{"key":"B33","doi-asserted-by":"publisher","first-page":"13647","DOI":"10.1073\/pnas.212516099","article-title":"DBC2, A candidate for a tumor suppressor gene involved in breast cancer","volume":"99","author":"Hamaguchi","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.7314\/APJCP.2012.13.5.2021","article-title":"Loss of DBC2 expression is an early and progressive event in the development of lung adenocarcinoma","volume":"13","author":"Dong","year":"2012","journal-title":"Asian Pac J Cancer Prev"},{"key":"B35","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.urolonc.2007.08.009","article-title":"DBC2 gene is silenced by promoter methylation in bladder cancer","volume":"26","author":"Shi","year":"2008","journal-title":"Urol Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1080\/02841860701644094","article-title":"Genetic analysis of the DBC2 gene in gastric cancer","volume":"47","author":"Cho","year":"2008","journal-title":"Acta Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1089\/cbr.2012.1386","article-title":"Downregulated RhoBTB2 expression contributes to poor outcome in osteosarcoma patients","volume":"28","author":"Jin","year":"2013","journal-title":"Cancer Biother Radiopharm"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.bbrc.2007.05.037","article-title":"Cyclin D1 down-regulation is essential for DBC2's Tumor suppressor function","volume":"358","author":"Yoshihara","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.3390\/cells9122648","article-title":"Cyclin D1 in cancer: a molecular connection for cell cycle control, adhesion and invasion in tumor and stroma","volume":"9","author":"Montalto","year":"2020","journal-title":"Cells"},{"key":"B40","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1080\/15384101.2019.1706903","article-title":"The double dealing of cyclin D1","volume":"19","author":"Tchakarska","year":"2020","journal-title":"Cell Cycle"},{"key":"B41","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.bbrc.2007.06.127","article-title":"DBC2 resistance is achieved by enhancing 26S proteasome-mediated protein degradation","volume":"360","author":"Collado","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"B42","doi-asserted-by":"publisher","first-page":"65","DOI":"10.31887\/DCNS.2020.22.1\/macrocq","article-title":"Neurodevelopmental disorders\u2014the history and future of a diagnostic concept","volume":"22","author":"Morris-Rosendahl","year":"2020","journal-title":"Dialogues Clin Neurosci"},{"key":"B43","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2013"},{"key":"B44","doi-asserted-by":"crossref","first-page":"41","DOI":"10.36255\/exon-publications-epilepsy-neurodevelopmental-disorders","article-title":"Overlap between epilepsy and neurodevelopmental disorders: insights from clinical and genetic studies","volume-title":"Epilepsy","author":"Shimizu","year":"2022"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1136\/jnnp-2020-324660","article-title":"Epilepsy, an orphan disorder within the neurodevelopmental family","volume":"91","author":"Shankar","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B46","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: position paper of the ILAE commission for classification and terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"key":"B47","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1136\/archdischild-2012-302882","article-title":"Investigating microcephaly","volume":"98","author":"Woods","year":"2013","journal-title":"Arch Dis Child"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e2021052138","DOI":"10.1542\/peds.2021-052138","article-title":"Evidence-informed milestones for developmental surveillance tools","volume":"149","author":"Zubler","year":"2022","journal-title":"Pediatrics"},{"key":"B49","doi-asserted-by":"publisher","first-page":"659064","DOI":"10.3389\/fneur.2021.659064","article-title":"Paroxysmal movement disorders","volume":"12","author":"Harvey","year":"2021","journal-title":"Front Neurol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S0022-3476(06)80003-X","article-title":"Alternating hemiplegia of childhood","volume":"122","author":"Bourgeois","year":"1993","journal-title":"J Pediatr"},{"key":"B51","doi-asserted-by":"publisher","first-page":"8434","DOI":"10.18632\/aging.103150","article-title":"Genetic regulatory subnetworks and key regulating genes in rat hippocampus perturbed by prenatal malnutrition: implications for major brain disorders","volume":"12","author":"Chen","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"B52","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1615\/CritRevNeurobiol.v17.i1.20","article-title":"On the use of neuro-2a neuroblastoma cells versus intact neurons in primary culture for neurotoxicity studies","volume":"17","author":"LePage","year":"2005","journal-title":"Crit Rev Neurobiol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/sj.leu.2403614","article-title":"CEBPA point mutations in hematological malignancies","volume":"19","author":"Leroy","year":"2005","journal-title":"Leukemia"},{"key":"B54","first-page":"97","article-title":"Apoptosis, bcl-2 family proteins and caspases: the ABCs of seizure-damage and epileptogenesis?","volume":"1","author":"Engel","year":"2009","journal-title":"Int J Physiol Pathophysiol Pharmacol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1074\/jbc.M705986200","article-title":"RhoBTB2 (DBC2) is a mitotic E2F1 target gene with a novel role in apoptosis","volume":"283","author":"Freeman","year":"2008","journal-title":"J Biol Chem"},{"key":"B56","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1038\/onc.2016.441","article-title":"DBC2\/RhoBTB2 functions as a tumor suppressor protein via musashi-2 ubiquitination in breast cancer","volume":"36","author":"Choi","year":"2017","journal-title":"Oncogene"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.4161\/cbt.10.11.13431","article-title":"Ectopic expression of RhoBTB2 inhibits migration and invasion of human breast cancer cells","volume":"10","author":"Ling","year":"2010","journal-title":"Cancer Biol Ther"},{"key":"B58","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1080\/17460441.2021.1883585","article-title":"Artificial intelligence, machine learning, and drug repurposing in cancer","volume":"16","author":"Tanoli","year":"2021","journal-title":"Expert Opin Drug Discov"},{"key":"B59","doi-asserted-by":"publisher","first-page":"910216","DOI":"10.3389\/frai.2022.910216","article-title":"The precision medicine process for treating rare disease using the artificial intelligence tool mediKanren","volume":"5","author":"Foksinska","year":"2022","journal-title":"Front Artif Intell"},{"key":"B60","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/FPC.0b013e32834f94cb","article-title":"Celecoxib pathways: pharmacokinetics and pharmacodynamics","volume":"22","author":"Gong","year":"2012","journal-title":"Pharmacogenet Genomics"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.3892\/ijo_00000418","article-title":"Synergistic effects of lovastatin and celecoxib on caveolin-1 and its down-stream signaling molecules: implications for colon cancer prevention","volume":"35","author":"Guruswamy","year":"2009","journal-title":"Int J Oncol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"e61836","DOI":"10.1371\/journal.pone.0061836","article-title":"Non-steroidal anti-inflammatory drugs decrease E2F1 expression and inhibit cell growth in ovarian cancer cells","volume":"8","author":"Valle","year":"2013","journal-title":"PLoS One"},{"key":"B63","doi-asserted-by":"publisher","first-page":"101025","DOI":"10.1016\/j.gimo.2024.101025","article-title":"O42: development of an anti-sense oligonucleotide therapeutic targeting RhoBTB2-related epileptic encephalopathy","volume":"2","author":"Wheeler","year":"2024","journal-title":"Genet Med Open"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2024.1448793\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T06:18:57Z","timestamp":1734329937000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2024.1448793\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,16]]},"references-count":63,"alternative-id":["10.3389\/fped.2024.1448793"],"URL":"https:\/\/doi.org\/10.3389\/fped.2024.1448793","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,16]]},"article-number":"1448793"}}